Jonathan Zager, MD Chief Academic Officer and Director of Regional Therapies at Moffitt Cancer Center, remarked, “The findings from this study reaffirm the critical role of melphalan/HDS in managing ...
Results show that percutaneous hepatic perfusion with CHEMOSAT® is an effective and safe treatment option for patients with advanced cholangiocarcinoma and has the potential to prolong life in ...
The American Medical Association announced a new health system textbook designed to train future physicians in modern healthcare. 1. The newly released textbook, Health Systems Science, is intended to ...
Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...
69 weeks (16 months) median hPFS in patients with uveal melanoma. 38 weeks (8.5 months) median hPFS in patients with cholangiocarcinoma. Importance of Repeated Treatments: The investigators’ approach ...
Delcath Receives Regulatory Approval to Commercialize Hepatic CHEMOSAT® Delivery System in Australia
NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced the Therapeutic Goods Administration (TGA) division of the Australian government has approved the Delcath ...
Overall Survival (OS): The study reported median OS of 22.4 months for patients treated with HEPZATO KIT as a first-line therapy (N=17) and 18.4 months as a second-line therapy (N=6). Hepatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback